MedPath

A randomized controlled study to examine the effects of a triple therapy with vonoprazan or rabeprazole against standard triple therapy-failed patients.

Not Applicable
Conditions
Helicobacter pylori infection
Registration Number
JPRN-UMIN000016601
Lead Sponsor
Juntendo University School of Medicine, Department of Gstroenterology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
70
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who cannot cancel a proton pump inhibitor for 2 weeks before judgment after re-eradication therapy. 2. Patients who have past history of drug allergy. 3. Patients who have severe diseases affecting the kidney, the heart, and the liver. 4. Patients who are pregnant, who may be pregnant, or who are nursing.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison on an eradication rate between a triple therapy with vonoprazan and a triple therapy with rabeprazole
Secondary Outcome Measures
NameTimeMethod
Comparison of adverse effects between a triple therapy with vonoprazan and a triple therapy with rabeprazole
© Copyright 2025. All Rights Reserved by MedPath